David M Markovitz

US Patent:

7641902, Jan 5, 2010

Filed:

Nov 20, 2006

Appl. No.:

11/601895

Inventors:

David M. Markovitz - Ann Arbor MI, US
Nirit Mor-Vaknin - Ann Arbor MI, US
Evan T. Keller - Ann Arbor MI, US
Christopher L. Hall - Ypsilanti MI, US
Susan M. Hiniker - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 39/395

US Classification:

4241301, 5303871

Abstract:

The present invention relates to compositions and methods for detecting cancer (e. g. , prostate cancer) and for inhibiting metastasis (e. g. , associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e. g. , prostate cancer). In addition, the present invention provides methods for inhibiting metastasis (e. g. , of prostate cancer) via altering (e. g. , inhibiting) vimentin expression and/or activity.

US Patent:

7691582, Apr 6, 2010

Filed:

Sep 24, 2003

Appl. No.:

10/670065

Inventors:

David M. Markovitz - Ann Arbor MI, US
Nirit Mor-Vaknin - Ann Arbor MI, US
Antonello Punturieri - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

G01N 33/53

US Classification:

435 71, 435 72, 435 732, 435325, 436501, 4241301

Abstract:

The present invention relates to methods for screening and modulating the bioavailability of extracellular secretory vimentin. In particular, the present invention provides inhibitors and activators of secretory vimentin including antibodies, small interfering RNAs, and antisense oligonucleotides. The present invention thus provides novel drug targets for enhanced anti-microbial response, and methods of using such modulators to beneficially alter the pathophysiologic effects of secretory vimentin.

US Patent:

20020137704, Sep 26, 2002

Filed:

Jun 11, 2001

Appl. No.:

09/878541

Inventors:

David Markovitz - Ann Arbor MI, US
Neil Faulkner - Ypsilanti MI, US
Brian Lane - Ann Arbor MI, US

International Classification:

A61K048/00
A61K031/35

US Classification:

514/044000, 514/454000

Abstract:

Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that inhibit cellular protein phosphatase 2A. Such methods are advantageous for treating viral infections such human immunodefeciency virus infections.

US Patent:

20030026802, Feb 6, 2003

Filed:

Sep 20, 2001

Appl. No.:

09/961696

Inventors:

David Markovitz - Ann Arbor MI, US
Brian Lane - Ann Arbor MI, US
Peter Polverini - Falcon Heights MN, US
Robert Strieter - Sherman Oaks CA, US

International Classification:

A61K039/395
A61K038/17

US Classification:

424/144100, 514/002000

Abstract:

Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.

US Patent:

20080261216, Oct 23, 2008

Filed:

Sep 10, 2007

Appl. No.:

11/852369

Inventors:

David Markovitz - Ann Arbor MI, US
Mark H. Kaplan - Ann Arbor MI, US
Michael H. Dosik - Setauket NY, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

C12Q 1/68
G01N 33/574
C12Q 1/02

US Classification:

435 6, 435 723, 435 29

Abstract:

The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers.

US Patent:

20090004197, Jan 1, 2009

Filed:

Oct 16, 2006

Appl. No.:

12/090164

Inventors:

David A. Markovitz - Ann Arbor MI, US
Nirit Mor-Vaknin - Ann Arbor MI, US
Michael Khodadoust - Ann Arbor MI, US
Barbara S. Adams - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 39/395
A61K 31/7105
C12Q 1/68
G01N 33/535

US Classification:

4241411, 514 44, 4241301, 435 6, 435 792

Abstract:

The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease.

US Patent:

20120135950, May 31, 2012

Filed:

May 21, 2010

Appl. No.:

13/321416

Inventors:

Mark H. Kaplan - Ann Arbor MI, US
David Markovitz - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 31/7072
A61K 31/7076
A61K 31/536
A61K 31/551
A61K 31/505
A61K 31/4418
A61K 31/427
A61K 31/635
A61K 31/496
A61P 35/00
C12Q 1/70
C40B 30/00
A61P 31/12
A61K 31/513
A61K 31/7068
A61K 31/52
A61K 31/708

US Classification:

514 45, 514 50, 514 81, 5142305, 514220, 514272, 514357, 514365, 514158, 51425301, 435 5, 506 7, 514274, 514 49, 5142634

Abstract:

Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.

US Patent:

20130096051, Apr 18, 2013

Filed:

Apr 11, 2011

Appl. No.:

13/640498

Inventors:

David Markovitz - Ann Arbor MI, US
Michael Swanson - Ann Arbor MI, US
Irwin Goldstein - East Ann Arbor MI, US
Harry Winter - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

C07K 14/42

US Classification:

514 24, 530370, 514 23, 514 37, 514 46, 514 33, 514 38, 4353201, 43525233

Abstract:

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity.